43rd Annual CFS: Innovative Cancer Therapy for Tomorrow™

Breakfast

Change Rooms (Exhibit Hall Open)

Welcome and Introductions

Smoldering and Newly Diagnosed Myeloma: When and How Much?

Early Relapse of Multiple Myeloma: When and on Whom to Use CAR T?

Optimizing the Treatment Sequence for Multiply Relapsed MM

Panel Discussion

Break (Exhibit Hall Open)

What's New in CLL?

Audience Q&A

What's New in Indolent Lymphomas?

What's New in DLBCL?

Panel Discussion: Using T-Cell Redirection in the Community: What Do You Need to Know?

Lunch

Integrating Novel Immunotherapies in the Treatment of ALL

Using JAK Inhibitors in Myelofibrosis Now and in the Future

Updates in Managing Systemic Mastocytosis

Rare Myeloid Malignancies: How to Recognize and Manage BPDCN and Overlaps

Refining Treatment Goals for CHIP and Lower-Risk MDS

Higher-Risk MDS: What to Do Now and What's Coming Next

Optimizing the Use of Targeted Therapies for Relapsed/Refractory AML

Cases and Conversations™: Optimizing Outcomes in PV and ET—Evolving Standards, Symptom Management, and Therapeutic Innovation (Spotlight CE Session)

Hematology Fellows Showdown!

Adjourn for the Day

Dinner

Targeting Cell Surface Markers Beyond PSMA in Prostate Cancer

Changing Treatment Landscape for Non–Muscle-Invasive Bladder Cancer

Use of ctDNA in Genitourinary Cancers: Is This Ready for Prime Time?

Novel Approaches to Combination Therapy in RCC

Panel Discussion and Q&A

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy (Spotlight CE Session)

The Future of Oncology in Practice Panel Introduction

The Future of Oncology in Practice Panel Discussion

Antibody-Drug Conjugates: Targets, Payloads, and Sequencing in HER2 "Negative" Disease

How to Manage the Axilla: An Oncologist’s Guide to Surgical De-Escalation

Fitting CDK4/6 Inhibitors in the Continuum of Care: From Adjuvant to Metastatic

How Do We Incorporate New Endocrine Therapies Into Clinical Practice?

Integrative Medicine: Evidence-Based Complementary Therapies for Holistic Patient Care

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics (Spotlight CE Session)

Management of Resectable EG Cancer

Targeting BRAF, KRAS, and HER2 in GI Tumors

Expert Opinion on Managing Anal Carcinoma

MSI-H Localized Colorectal Cancer: Systemic Therapy and Organ Preservation

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers (Spotlight CE Session)

NSCLC With Gene Fusions: What's Coming Next?

New Combos and New Questions for EGFR-Mutant Advanced NSCLC

Stage I-III Is Not What It Used to Be

Antibody-Drug Conjugates in NSCLC: Where Do They Fit?

Sea Changes in Small Cell Lung Cancer

Lung Cancer: Hot Topics Grab Bag

Name That Curve!

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights (Spotlight CE Session)

Redefining the Treatment Landscape in HER2-Mutant NSCLC: Applying New Tools in Practice (Spotlight CE Session)